Day 1

8:00 AM-8:30 AM  Continental Breakfast and Registration

8:30 AM-8:45 AM  Welcome from Symposium Co-Chairs
Stanton F. McHardy, Ph.D., Co-Director, Center for Innovative Drug Discovery, Director, Max and Minnie Tomerlin Voelcker Medicinal Chemistry Core Facility, UTSA
Matt Hart, Ph.D., Director, Center for Innovative Drug Discovery High Throughput Screening Core Facility, UTHSCSA

8:45-9:00 AM  Introductory remarks
Dean George Perry, Ph.D., Semmes Foundation Distinguished University Chair in Neurobiology, Dean of the College of Sciences and Professor of Biology, UTSA

9:00 AM-9:50 AM  Plenary Keynote Presentation  Session Chair: Stanton McHardy, Ph.D.
Craig Lindsley, Ph.D., William K. Warren, Jr. Chair in Medicine, Professor of Pharmacology and Chemistry, Director, Medicinal Chemistry, Vanderbilt University
“Title TBD”

9:50 AM-10:10 AM  Coffee Break

10:10 AM-12:10 PM  Session One  Session Chair: Bruce Nicholson, Ph.D.
Identifying and Characterizing Molecular Drug Targets

10:10 AM-10:40 AM  Michael White, Professor, Cell Biology, Associate Director, Simmons Comprehensive Cancer Center, Sherry Wigley Crow Endowed Chair in Cancer Research, Grant A. Dove Distinguished Chair for Research in Oncology UT Southwestern Medical Center
“Targeting mechanistic subtypes of neoplastic disease”

10:40 AM-11:10 AM  Gaston Habets, Ph.D., Sr. Director of Assay & Research Operations, Plexxikon Inc.
“From drug targets to INDs, a cycle driven by Scaffold-Based Drug Discovery”

11:10 AM-11:40 AM  Peter J. A. Davies, M.D., Ph.D., Professor & Director, Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston
“The Gulf Coast Consortium Combinatorial Drug Discovery Program”

11:40 AM-12:10 PM  Gregory Cuny, Ph.D., Assistant Professor of Medicinal Chemistry, Department of Pharmacological and Pharmaceutical Sciences, University of Houston
“CpIMPDH: A Molecular Target for Cryptosporidiosis”

12:15 PM-1:30 PM  Lunch
1:30 PM-3:00 PM  
**Session Two**  
*Assay Development and Identifying Lead Compounds*

**Session Chair:** Mart Hart, Ph.D.

1:30 PM-2:00 PM  
Bruce Posner, Ph.D.  
Director, HTS/RNAi Screening Core, Professor, Biochemistry Department, U.T. Southwestern Medical Center  
“Identification and Characterization of Potentiators of Tissue Regeneration”

2:00 PM-2:30 PM  
Stan Watowich, Ph.D.,  
Associate Professor, Department of Biochemistry & Molecular Biology, UTMB Galveston  
Title “TBD”

2:30 PM-3:00 PM  
Conor Caffrey,  
Associate Professor, Center for Discovery and Innovation in Parasitic Diseases,  
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego  
“Identifying hits and leads for (neglected) parasitic diseases of poverty at the CDIPD”

3:00 PM-3:30 PM  
John Hart, Ph.D.,  
Ewing Halsell/President’s Council Distinguished Chair in Biochemistry, UTHSCSA  
“Towards inhibitors of CARDS toxin, a M. pneumoniae virulence factor involved in walking pneumonia and asthma”

3:30 PM-3:50 PM  
**Coffee Break**

3:50 PM-5:00 PM  
**Session Three**  
*Medicinal Chemistry and Drug Discovery*

**Session Chair:** Stan McHardy, Ph.D.

3:50 PM-4:20 PM  
Stephen Martin, Ph.D., M. June and J. Virgil Waggoner Regents Chair in Chemistry, Department of Chemistry, UT Austin  
“Progress toward a Novel Approach to Treat Neurodegenerative Diseases”

4:20 PM-4:50 PM  
Jef De Brabander, Ph.D., Julie and Louis Beecherl Jr. Chair in Medical Science, Department of Biochemistry, UT Southwestern  
“The First Targeted Approach Towards APC-Mutated Colon Cancer: From Discovery Biology To Pre-Clinical Efficacy”

5:00 PM-7:00 PM  
**Wine and Cheese Social and Poster Session**

---

**Day 2**

8:00 AM-8:30 AM  
**Continental Breakfast**

8:30 AM-10:45 AM  
**Session Four**  
*Developing Novel Therapeutic Approaches to Cancer*

**Session Chair:** Doug Frantz, Ph.D.

8:30 AM-9:00 AM  
Phil Jones, Ph.D., Executive Director and Head of Drug Discovery, Institute for Applied Cancer Science, MD Anderson  
“I Institute For Applied Cancer Science, Developing the Next Generation of Oncology Agents for Targeted Patient Populations”

9:00 AM-9:30 AM  
Graham Beaton, Ph.D., Vice President Medicinal Chemistry, Curtana Inc.  
“Cancer Stem Cell Targeted Therapeutics for the Treatment of Glioblastoma and Other Brain Cancers”

9:30 AM-9:55 AM  
Rong Li, Ph.D., Professor, Department of Molecular Medicine, UTHSCSA  
“Targeting ER-beta Signaling as a Novel Anticancer Therapy”
9:55 AM-10:20 AM  Susan Mooberry, Ph.D., Professor, Greehey Distinguished Chair in Targeted Molecular Therapeutics, Department of Pharmacology, UTHSCSA  “Drug Discovery for Triple Negative Breast Cancers”

10:20 AM-10:40 AM  Coffee Break

10:40 AM-12:30 PM  Session Five  Session Chair: Veronica Galvan, Ph.D.  Therapies in Regenerative Medicine and Brain Health

10:40 AM-11:10 AM  Bob Messing, M.D., Associate Dean for Research Development at Dell Medical School, Department of Pharmacology, UT Austin Dell Medical School  “Targeting protein kinase C epsilon to develop novel therapeutics against pain and addiction”

11:10 AM-11:40 AM  Thomas Knott, Ph.D., CSO, Cytocentrics Inc.  “Cellular physiology of patient derived cells as a future diagnostics”

11:40 PM-12:10 PM  George Perry, Ph.D., Semmes Foundation Distinguished University Chair in Neurobiology, Dean of the College of Sciences and Professor of Biology, UTSA  Title “Oxidative stress: a therapeutic window to Alzheimer disease”

12:10 PM-12:35 PM  Luke Lairson, Assistant Professor of Chemistry, Department of Chemistry, The Scripps Research Institute, California Campus  Title “TBD”

12:35 PM-1:45 PM  Lunch

1:45 PM-3:30 PM  Session Six  Session Chair: Steven Saville, Ph.D.  Infectious Disease

1:45 PM-2:15 PM  Rob Davey, Ph.D., Interim Chair, Scientist and Ewing Halsell Scholar, Department of Virology and Immunology, Texas Biomedical Research  “High throughput compound screening at high containment: new targets for Ebolavirus therapy”

2:15 PM-2:40 PM  Jose Lopez Ribot, Ph.D., Professor, Margaret Batts Tobin Distinguished Chair, Department of Biology, UTSA  “Anti-virulence approaches for antifungal drug development”

2:40 PM-3:05 PM  Phil LoVerde, Ph.D., Professor, Department of Biochemistry and Pathology, UTHSCSA  “Genetic basis of drug resistance in Schistosoma, development of novel therapeutics and biomarkers for human schistosomiasis”

3:05 PM-3:30 PM  Kirsten Hanson, Ph.D., Assistant Professor, Department of Biology, UTSA  “Plasmodium liver stage phenotypic profiling for antimalarial drug discovery”

3:30-3:45 PM  Coffee Break

3:45-4:45  Panel Discussion
Panel Members:
Craig Lindsley
Phil Jones
Jef De Brabander

Panel Facilitators: Stan McHardy and Doug Frantz

5:00  Adjourn